Top Stories
Novartis is working with CAS, a division of the American Chemical Society, while AbbVie has teamed up with Valkai for custom AI tools.
Ortet is focused on improving personalised healthcare.
The smart ring maker had planned to raise up to $2.1 billion through the sale of 50 million shares.
The company said one AI-supported drug discovery programme moved from lead identification to a clinical candidate twice as fast as historical timelines.
Tempus AI is building a portfolio that can "identify signals across numerous types of heart and vascular disease from the same ECG," cardiology SVP Brandon Fornwalt said.
Conference News
Study explores RNA biomarkers for prognostic and potential MRD assessment in locally advanced, non-resectable stage III lung cancerHEIDELBERG, Germany--(BUSINESS WIRE)-- Hummingbird Diagnostics GmbH, ...
MILAN, Sept. 30, 2026 /PRNewswire/ -- Sinocare is showcasing its integrated chronic disease management portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD ...
Debut research presented at EASD2026 reveals outcomes among patients on Ro's platform who switched from an injectable GLP-1 to the Wegovy® pillNEW YORK, Sept. 30, 2026 /PRNewswire/ -- Ro, the leading ...
About one in three people in the UK living with the condition don't know they have it. Our technology can help find them sooner, with far fewer blood tests and more time for people to stay well. We ar...
A real-world study of 8,391 patients found that autonomous artificial intelligence (AI) could free up enough clinical capacity to provide more than 8,500 additional face-to-face dermatology appointmen...
